Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) has provided an update.
Oxford Biomedica announced that Dr. Roch Doliveux, Non-Executive Director and Chair of the company, purchased 67,000 ordinary shares on the London Stock Exchange. This transaction, valued at approximately £301,332.50, reflects a strategic move by a key company leader, potentially signaling confidence in the company’s market position and future prospects.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall stock score reflects strong technical indicators and positive corporate events, which are offset by financial instability and valuation concerns. The earnings call provided a positive outlook, but the company’s high leverage and negative profitability remain significant risks.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, the company is a pioneer in viral vectors, collaborating with leading pharmaceutical and biotechnology firms. OXB offers expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types, supporting clients from early-stage development to commercialization. Headquartered in Oxford, UK, OXB operates facilities in the UK, France, and the US.
Average Trading Volume: 148,127
Technical Sentiment Signal: Hold
Current Market Cap: £466.7M
Learn more about OXB stock on TipRanks’ Stock Analysis page.